This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Identification of NET-related inflammatory biomarkers using BALF and TA diagnostic tools
Timeframe: 2 years
Quantification of NET-related inflammatory biomarkers using BALF and TA diagnostic tool
Timeframe: 2 years
Correlation of NET-related inflammatory markers using BALF and TA diagnostic tool with the extent of metastatic dissemination
Timeframe: 2 years